180-Day Exclusivity: When Everybody's Special, Nobody's Special

It is very unusual for a Hatch-Waxman exclusivity issue to intersect with a Pixar movie. But a recent viewing of The Incredibles got me thinking about FDA’s 2016 final regulation regarding 180-day exclusivity, particularly its new rule that an ANDA… Read More
Read More

NCEs+Old Antibiotics: The Wrong Combination?

For many things in life, details matter. Take cooking, for instance: add the wrong ingredient or combine your ingredients in the wrong order, and you may have an unexpected disaster rather than a prize-winning pie. Trust me, you don’t want to eat a… Read More
Read More

Court Drops Depth Charge on Submarine Exclusivity

On July 22, 2019, the United States District Court for the District of Columbia ruled against the Food and Drug Administration (“FDA”) in a lawsuit challenging FDA’s application of 3-year exclusivity in the context of a 505(b)(2) application. T… Read More
Read More

Orphan Drug Designation: The Gift That Keeps on Giving

In the world of exclusivity, there is one overarching rule: all good things must come to an end. New chemical entity (NCE) exclusivity expires after five years (sometimes four); orphan drug exclusivity ends after seven years; and even Reference Produ… Read More
Read More
Categories: Orphan

Submarine Exclusivity: Unseen Risk for 505(b)(2) Applications

Last week, the Food and Drug Administration (FDA) finalized its guidance on Determining Whether to Submit an ANDA or a 505(b)(2) Application. The final guidance provides useful tips on the differences between ANDAs and 505(b)(2) applications and the… Read More
Read More

Exclusivity Rules Blog — Welcome

Welcome to the new Exclusivity Rules blog, sponsored by Lassman Law+Policy.  As the name suggests, this blog will focus on the complex rules – both written and unwritten – that govern FDA’s exclusivity decisions for drugs and biologics. The bl… Read More
Read More
Categories: Other